Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib.
about
Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.Targeted drugs for systemic therapy of lung cancer with brain metastases.The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations.
P2860
Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Second-line Treatment of Non-S ...... al Development of Dacomitinib.
@en
type
label
Second-line Treatment of Non-S ...... al Development of Dacomitinib.
@en
prefLabel
Second-line Treatment of Non-S ...... al Development of Dacomitinib.
@en
P2093
P2860
P356
P1476
Second-line Treatment of Non-S ...... al Development of Dacomitinib.
@en
P2093
Asunción Díaz
Elisabeth Jimenez
Jon Zugazagoitia
Juan Antonio Nuñez
Lara Iglesias
Luis Paz-Ares
Santiago Ponce-Aix
P2860
P356
10.3389/FMED.2017.00036
P577
2017-04-05T00:00:00Z